Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.01583-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Allan Kengo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Clofazimine, Drug Interactions, Tuberculosis, Multidrug-Resistant, Antitubercular Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership, HHS | NIH | National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Clofazimine is included in drug regimens to treat rifampicin/drug-resistant tuberculosis (DR-TB), but there is little information about its interaction with other drugs in DR-TB regimens. We evaluated the pharmacokinetic interaction between clofazimine and isoniazid, linezolid, levofloxacin, and cycloserine, dosed as terizidone. Newly diagnosed adults with DR-TB at Klerksdorp/Tshepong Hospital, South Africa, were started on the then-standard treatment with clofazimine temporarily excluded for the initial 2 weeks. Pharmacokinetic sampling was done immediately before and 3 weeks after starting clofazimine, and drug concentrations were determined using validated liquid chromatography-tandem mass spectrometry assays. The data were interpreted with population pharmacokinetics in NONMEM v7.5.1 to explore the impact of clofazimine co-administration and other relevant covariates on the pharmacokinetics of isoniazid, linezolid, levofloxacin, and cycloserine. Clofazimine, isoniazid, linezolid, levofloxacin, and cycloserine data were available for 16, 27, 21, 21, and 6 participants, respectively. The median age and weight for the full cohort were 39 years and 52 kg, respectively. Clofazimine exposures were in the expected range, and its addition to the regimen did not significantly affect the pharmacokinetics of the other drugs except levofloxacin, for which it caused a 15% reduction in clearance. A posteriori power size calculations predicted that our sample sizes had 97%, 90%, and 87% power at P < 0.05 to detect a 30% change in clearance of isoniazid, linezolid, and cycloserine, respectively. Although clofazimine increased the area under the curve of levofloxacin by 19%, this is unlikely to be of great clinical significance, and the lack of interaction with other drugs tested is reassuring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
- Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa.
- Bioengineering and Integrated Genomics Group, Council for Scientific and Industrial Research, Pretoria, South Africa.
- Johns Hopkins University Center for Tuberculosis Research, Division of Infectious Diseases, School of Medicine, Baltimore, Maryland, USA.
- Department of Internal Medicine, University of the Witwatersrand, Klerksdorp/Tshepong Hospital Complex North-West Province, Klerksdorp-Tshepong, South Africa.
ORCID-Profile: Allan Kengo, Paolo Denti, Juan Eduardo Resendiz-Galvan
Förderung
- NIAID NIH HHS
- EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership
- HHS | NIH | National Institute of Allergy and Infectious Diseases
- South African Medical Research Council
Zitieren
APA
Kengo, A., Nabeemeeah, F., Denti, P., Sabet, R., Okyere-Manu, G., Abraham, P., Weisner, L., Mosala, M. H., Tshabalala, S., Scholefield, J., Resendiz-Galvan, J. E., Martinson, N. A., & Variava, E. (2024). Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01583-23
Vancouver
Kengo A, Nabeemeeah F, Denti P, Sabet R, Okyere-Manu G, Abraham P, et al. Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01583-23
BibTeX
@article{Kengo2024,
author = {Kengo, Allan and Nabeemeeah, Firdaus and Denti, Paolo and Sabet, Ryan and Okyere-Manu, Gifty and Abraham, Pattamukkil and Weisner, Lubbe and Mosala, Modiehi Helen and Tshabalala, Sibongile and Scholefield, Janine and Resendiz-Galvan, Juan Eduardo and Martinson, Neil A and Variava, Ebrahim},
title = {Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01583-23}
}
EUVIMED